BBIO ▼ -0.1% - BridgeBio Pharma, Inc. $BBIO Morgan Stanley raised the firm's price target on BridgeBio Pharma to $91 from $88 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets among its biotechnology coverage following Q3 earnings. 13-NOV-2026 08:20 AM ET